Search

Your search keyword '"Schetelig, Johannes"' showing total 222 results

Search Constraints

Start Over You searched for: Author "Schetelig, Johannes" Remove constraint Author: "Schetelig, Johannes" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
222 results on '"Schetelig, Johannes"'

Search Results

1. How risky is a second allogeneic stem cell transplantation?

2. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

3. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

4. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

7. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

9. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

12. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

13. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

14. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

15. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

16. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

18. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

19. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

20. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

24. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

25. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation

27. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

28. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

29. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

30. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

31. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

32. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

33. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation

34. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

35. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS

36. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

37. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

38. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.

40. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

41. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

42. The clinical mutatome of core binding factor leukemia

47. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies.

49. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial

50. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial

Catalog

Books, media, physical & digital resources